The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

The clinical management of tacrolimus, a macrolide used as immunosuppressant after
transplantation, is complicated by its narrow therapeutic index in combination with inter-and …

Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under
clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after …

CYP3A is one of the most important cytochrome P450 isoforms responsible for drug
metabolism by humans because it is the major such enzyme in critical tissues such as the …

Pregnancy after solid organ transplantation, although considered high risk for maternal,
fetal, and neonatal complications, has been quite successful. Tacrolimus pharmacokinetic …

The relationship between the dose of tacrolimus, trough tacrolimus blood concentration, and
selected clinical endpoints (acute rejection, nephrotoxicity, and other toxicities) were …

Objective Tacrolimus, an immunosuppressive drug widely prescribed in kidney
transplantation, requires therapeutic drug monitoring due to its marked interindividual …

The calcineurin inhibitors cyclosporine and tacrolimus form the cornerstones of most
immunosuppression protocols. Because of their variable pharmacokinetics, and their narrow …

Purpose The aim of this study was to evaluate the effect of different clinical covariates on
tacrolimus dose requirements in adult kidney transplant patients with a specific focus on …

Immunosuppressant-induced nephrotoxicity, in particular chronic progressive
tubulointerstitial fibrosis/arteriopathy induced by the calcineurin inhibitors cyclosporin and …